News
AMRN
0.5486
+4.52%
0.0237
AMARIN CORP - NASDAQ GRANTED 180 DAYS TO REGAIN NASDAQ COMPLIANCE
Reuters · 14h ago
After Plunging -19.13% in 4 Weeks, Here's Why the Trend Might Reverse for Amarin (AMRN)
NASDAQ · 3d ago
Top 3 Health Care Stocks You'll Regret Missing In Q4
Benzinga · 3d ago
Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), Bolt Biotherapeutics (BOLT) and Amarin (AMRN)
TipRanks · 4d ago
Weekly Report: what happened at AMRN last week (1111-1115)?
Weekly Report · 5d ago
Amarin Corporation Announces That Investigators Will Present An Additional Subgroup Analysis From The REDUCE-IT Outcomes Trial In Patients With And Without Coronary Artery Disease History And Mechanistic Data On Eicosapentaenoic Acid At The American Heart Association's Scientific Sessions
Benzinga · 11/11 13:22
Amarin announces to present additional analysis from REDUCE-IT outcomes trial
TipRanks · 11/11 13:22
Weekly Report: what happened at AMRN last week (1104-1108)?
Weekly Report · 11/11 09:53
Krystal Q3 Earnings and Sales Top Estimates, Vyjuvek Gains Traction
NASDAQ · 11/05 18:58
Weekly Report: what happened at AMRN last week (1028-1101)?
Weekly Report · 11/04 09:53
Bausch Health Q3 Earnings and Revenues Top, Xifaxan Boosts Sales
NASDAQ · 11/01 17:42
Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus
NASDAQ · 11/01 14:18
Bristol-Myers Tops Q3 Earnings and Sales Estimates, Ups 2024 EPS View
NASDAQ · 10/31 15:10
Biotech Alert: Searches spiking for these stocks today
TipRanks · 10/31 15:05
Amarin's Q3 Earnings In Line, Revenues Fall Shy of Estimates
NASDAQ · 10/31 13:32
Amarin Corporation: Q3 Highlights and Future Outlook
TipRanks · 10/31 04:26
Based on the provided financial report, the title of the article is: "Amarin Corporation plc Quarterly Report (Form 10-Q)
Press release · 10/31 03:10
AMARIN CORP : QTRLY NON-GAAP ADJUSTED BASIC AND DILUTED LOSS PER SHARE OF $0.05
Reuters · 10/30 20:56
Amarin sees current cash, investments, other assets to support operations
TipRanks · 10/30 20:50
Amarin Non-GAAP EPS of -$0.05 beats by $0.01, revenue of $42.3M misses by $2.21M
Seeking Alpha · 10/30 20:13
More
Webull provides a variety of real-time AMRN stock news. You can receive the latest news about Amarin through multiple platforms. This information may help you make smarter investment decisions.
About AMRN
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.